• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗磷脂抗体不同患者组中蛋白S和C4b结合蛋白水平的差异。

Differences in protein S and C4b-binding protein levels in different groups of patients with antiphospholipid antibodies.

作者信息

Forastiero R R, Kordich L, Basilotta E, Carreras L O

机构信息

University Institute of Biomedical Sciences, Favaloro Foundation, Buenos Aires, Argentina.

出版信息

Blood Coagul Fibrinolysis. 1994 Aug;5(4):609-16.

PMID:7841319
Abstract

Total protein S (tPS), free protein S (fPS) and C4b-binding protein (C4b-BP) were measured by immunological assays in 73 patients with antiphospholipid (aPL) antibodies, in order to determine whether the previously reported abnormalities in PS levels in this group of patients could be related to the presence of lupus anticoagulant (LA) or anticardiolipin (aCL) antibodies. As compared with the normal controls (n = 44), the authors found a significant decrease of tPS, fPS and C4b-BP in 45 LA(+)aCL(+) patients (P < 0.001), a decrease of tPS (P < 0.001), fPS and C4b-BP (P < 0.01) in eight LA(-)aCL(+) patients and a decrease of only fPS (P < 0.05) in 20 LA(+)aCL(-) patients. There was no difference in the levels of tPS, fPS and C4b-BP between LA(+)aCL(+) and LA(-)aCL(+) patients. In contrast, the LA(+)aCL(+) patients had lower values of tPS, fPS and C4b-BP than LA(+)aCL(-) patients (P < 0.05). In some patients, protein S activity (PSact) was also measured and a high correlation was observed between fPS antigen and PSact (r = 0.93, P < 0.001). The data show that the presence of aCL antibodies is associated with a probably acquired deficiency of PS and C4b-BP. On the other hand, in LA patients without a CL antibodies, the fPS deficiency is unrelated to an increase in C4b-BP levels and may be due to abnormal binding of PS to C4b-BP.

摘要

采用免疫分析法对73例抗磷脂(aPL)抗体患者检测了总蛋白S(tPS)、游离蛋白S(fPS)和C4b结合蛋白(C4b - BP),以确定先前报道的该组患者PS水平异常是否与狼疮抗凝物(LA)或抗心磷脂(aCL)抗体的存在有关。与正常对照组(n = 44)相比,作者发现45例LA(+)aCL(+)患者的tPS、fPS和C4b - BP显著降低(P < 0.001),8例LA(-)aCL(+)患者的tPS降低(P < 0.001)、fPS和C4b - BP降低(P < 0.01),20例LA(+)aCL(-)患者仅fPS降低(P < 0.05)。LA(+)aCL(+)和LA(-)aCL(+)患者之间的tPS、fPS和C4b - BP水平无差异。相比之下,LA(+)aCL(+)患者的tPS、fPS和C4b - BP值低于LA(+)aCL(-)患者(P < 0.05)。在一些患者中还检测了蛋白S活性(PSact),并观察到fPS抗原与PSact之间高度相关(r = 0.93,P < 0.001)。数据表明,aCL抗体的存在与可能获得性的PS和C4b - BP缺乏有关。另一方面,在无aCL抗体的LA患者中,fPS缺乏与C4b - BP水平升高无关,可能是由于PS与C4b - BP的异常结合所致。

相似文献

1
Differences in protein S and C4b-binding protein levels in different groups of patients with antiphospholipid antibodies.抗磷脂抗体不同患者组中蛋白S和C4b结合蛋白水平的差异。
Blood Coagul Fibrinolysis. 1994 Aug;5(4):609-16.
2
Antithrombin, protein S and protein C and antiphospholipid antibodies in systemic lupus erythematosus.系统性红斑狼疮中的抗凝血酶、蛋白S、蛋白C及抗磷脂抗体
Sangre (Barc). 1998 Oct;43(5):345-8.
3
The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.IgA抗磷脂检测在系统性红斑狼疮抗磷脂(休斯)综合征诊断中的价值。
J Rheumatol. 2001 Dec;28(12):2637-43.
4
[Antiphospholipid syndrome and stroke].[抗磷脂综合征与中风]
Rinsho Shinkeigaku. 2005 Nov;45(11):852-5.
5
Antiphospholipid antibodies and thrombosis in systemic lupus erythematosus: comparison of three lupus anticoagulant assays and anticardiolipin ELISA in 188 patients.系统性红斑狼疮中的抗磷脂抗体与血栓形成:188例患者中三种狼疮抗凝物检测方法与抗心磷脂酶联免疫吸附测定的比较
Blood Coagul Fibrinolysis. 1992 Aug;3(4):407-14.
6
IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.对于临床怀疑抗磷脂抗体综合征的患者,与磷脂结合的β2糖蛋白I的IgG反应性是通过添加六方(II)相磷脂淬灭的狼疮抗凝活性部分的主要决定因素。
Haematologica. 1999 Sep;84(9):829-38.
7
Antiphospholipid antibody tests: spreading the net.抗磷脂抗体检测:扩大范围
Ann Rheum Dis. 2005 Nov;64(11):1639-43. doi: 10.1136/ard.2005.035824. Epub 2005 Apr 7.
8
Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men.抗磷脂抗体和蛋白S缺乏与HIV感染男性血栓形成的相关性
Blood Coagul Fibrinolysis. 1994 Aug;5(4):455-62.
9
The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.β2糖蛋白I依赖性狼疮抗凝物在抗磷脂综合征发病机制中的作用
Verh K Acad Geneeskd Belg. 2000;62(5):353-72.
10
Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.狼疮抗凝物和抗心磷脂抗体与系统性红斑狼疮、原发性抗磷脂综合征及其他疾病患者血栓形成的关联
Isr J Med Sci. 1992 Jan;28(1):9-15.

引用本文的文献

1
Coexistence Between Antiphospholipid Syndrome and Protein S Deficiency in a Patient With Transverse Sinus Thrombosis: A Rare Association.一名横窦血栓形成患者抗磷脂综合征与蛋白S缺乏症并存:一种罕见的关联。
Clin Case Rep. 2024 Dec 5;12(12):e9663. doi: 10.1002/ccr3.9663. eCollection 2024 Dec.
2
The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.抗磷脂综合征与动脉粥样硬化:发病机制线索
Curr Rheumatol Rep. 2003 Oct;5(5):401-6. doi: 10.1007/s11926-003-0032-6.
3
Graves' disease associated with anticardiolipin antibody positivity and acquired protein S deficiency.
格雷夫斯病合并抗心磷脂抗体阳性及获得性蛋白S缺乏症。
Rheumatol Int. 2003 Jul;23(4):198-200. doi: 10.1007/s00296-003-0291-6. Epub 2003 Feb 26.
4
What causes the antiphospholipid syndrome?抗磷脂综合征的病因是什么?
Curr Rheumatol Rep. 2001 Aug;3(4):293-300. doi: 10.1007/s11926-001-0033-2.
5
Clinical trials for the antiphospholipid syndrome.抗磷脂综合征的临床试验
Curr Rheumatol Rep. 2000 Jun;2(3):233-7. doi: 10.1007/s11926-000-0084-9.
6
Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.抗心磷脂抗体通过β2-糖蛋白I(β2-GPI)与蛋白C结合:抗磷脂抗体对蛋白C系统产生抑制作用的一种可能机制。
Clin Exp Immunol. 1998 May;112(2):325-33. doi: 10.1046/j.1365-2249.1998.00582.x.